Q32 Bio Inc. (NASDAQ:QTTB - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $32.17.
A number of analysts have issued reports on the company. Mizuho raised Q32 Bio to a "strong-buy" rating in a report on Monday, September 7th. Morgan Stanley initiated coverage on Q32 Bio in a research report on Monday, August 24th. They set an "overweight" rating and a $34.00 price objective for the company. HC Wainwright increased their price objective on Q32 Bio from $13.00 to $36.00 and gave the company a "buy" rating in a report on Tuesday, July 28th. Cantor Fitzgerald reissued an "overweight" rating on shares of Q32 Bio in a research report on Wednesday, September 16th. Finally, Jefferies Financial Group initiated coverage on Q32 Bio in a research note on Monday, September 28th. They set a "buy" rating and a $29.00 target price for the company.
Check Out Our Latest Report on Q32 Bio
Q32 Bio Trading Down 4.8%
Q32 Bio stock opened at $8.29 on Friday. The stock has a market cap of $248.04 million, a P/E ratio of 3.66 and a beta of 0.45. The company has a fifty day simple moving average of $9.14 and a 200-day simple moving average of $9.50. Q32 Bio has a 12-month low of $1.90 and a 12-month high of $23.57.
Q32 Bio (NASDAQ:QTTB - Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.07. As a group, sell-side analysts forecast that Q32 Bio will post -1.42 earnings per share for the current fiscal year.
Insider Activity at Q32 Bio
In other Q32 Bio news, CFO Lee Kalowski sold 3,972 shares of the firm's stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total transaction of $65,776.32. Following the sale, the chief financial officer owned 138,471 shares of the company's stock, valued at approximately $2,293,079.76. This trade represents a 2.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shelia M. Violette sold 2,798 shares of the business's stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $16.56, for a total transaction of $46,334.88. Following the sale, the insider owned 127,771 shares of the company's stock, valued at $2,115,887.76. This represents a 2.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 22,054 shares of company stock valued at $320,397 over the last three months. 34.46% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. Atlas Venture Life Science Advisors LLC increased its position in shares of Q32 Bio by 29.9% during the second quarter. Atlas Venture Life Science Advisors LLC now owns 2,717,106 shares of the company's stock worth $34,616,000 after purchasing an additional 625,000 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Q32 Bio by 450.3% in the 3rd quarter. Marshall Wace LLP now owns 368,935 shares of the company's stock valued at $3,051,000 after purchasing an additional 301,890 shares during the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of Q32 Bio in the 3rd quarter valued at about $2,387,000. BlackRock Inc. acquired a new stake in shares of Q32 Bio in the 2nd quarter valued at about $1,510,000. Finally, Renaissance Technologies LLC boosted its position in shares of Q32 Bio by 107.7% in the 1st quarter. Renaissance Technologies LLC now owns 206,915 shares of the company's stock valued at $1,328,000 after purchasing an additional 107,315 shares during the period. Institutional investors and hedge funds own 31.32% of the company's stock.
Q32 Bio Company Profile
(
Get Free Report)
Q32 Bio is a biotechnology company focused on developing treatments for autoimmune and inflammatory diseases by targeting pathways that regulate the immune system. Its research has centered on biologic medicines designed to restore immune balance and address disease mechanisms. The company's programs have included ADX-097, a complement C3 inhibitor designed to target activity in affected tissues, and ADX-914, an antibody targeting the interleukin-7 receptor alpha. Q32 Bio has been based in the United States and has advanced its programs through clinical development.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Q32 Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Q32 Bio wasn't on the list.
While Q32 Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.